Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study

Kidney International

Volumn 45, Issue 5, 1994, Pages 1477-1483

  Sreedhara, Rajanna ^b   Himmelfarb, Jonathan ^b   Lazarus, J Michael ^b   Hakim, Raymond M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLITEF IMPLANT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

EID: 0028280208     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1994.192     Document Type: Article

References (48)

1. FELDMAN HI, HELD PJ, HUTCHINSON JT, STOIBER E, HARTIGAN MF, BERLIN JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 43:1091-1096, 1993
2. WINDUS DW: Permanent vascular access: A Nephrologist's view. Am J Kidney Dis 21:457-471, 1993
3. WINSETT OE, WOLMA FJ: Complications of vascular access for hemodialysis. South Med J 78:513-517, 1985
4. EGGERS PW: Internal Record, HCFA. 1992
5. AL-MOMEN AK, HURAIB SO: Low-dose danazol for vascular access and dialyzer thrombosis in hemodialysis patients. Haemostasis 22:12-16, 1992
6. MUNDA R, FIRST R, ALEXANDER WJ, LINNEMANN CC, FIDLER JP, KITTUR D: Polytetrafluoroethylene graft survival in hemodialysis. JAMA 249:219-222, 1983
7. PADLER SB, KIRKMAN RL, WHITTEMORE AD, HAKIM RM, LAZARUS MJ, TILNEY NL: Vascular access for hemodialysis. Ann Surg 202:235-239, 1985
8. RAJU S: PTFE grafts for hemodialysis access. Ann Surg 206:666-673, 1987
9. KAEGI A, PINEO GF, SHIMIZU A, TRIVEDI H, HIRSH J, GENT M: Arteriovenous-shunt thrombosis. N Engl J Med 290:304-306, 1974
10. HARTER HR, BURCH JW, MAJERUS PW, STANFORD N, DELMEZ JA, ANDERSON CB, WEERTS CA: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 301:577-579, 1979
11. EMMONS PR, HARRISON MJG, HONOUR AJ, MITCHELL JRA: Effect of Dipyridamole on human platelet behaviour. Lancet ii:603-606, 1965
12. HAGEN P, WANG Z, MIKAT EM, HACKEL DB: Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates. Ann Surg 195:328-339, 1982
13. BROTHERS TE, VINCENT CK, DARVISHIAN D, HARRELL KA, BURKEL WE, STANLEY JC, GRAHAM LM: Effects of acetylsalicylic acid administration on patency and anastomotic hyperplasia of ePTFE grafts. ASAIO Trans 35:558-560, 1989
14. CLYNE CAC, ARCHER TJ, ATUHAIRE LK, CHANT ADB, WEBSTER JHH: Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg 74:246-248, 1987
15. WINDUS DW, JENDRISAK MD, DELMEZ JA: Prosthetic fistula survival and complications in hemodialysis patients: Effects of diabetes and age. Am J Kidney Dis 19:448-452, 1992
16. CHURCHILL DN, TAYLOR W, COOK RJ, LAPLANTE P, BARRE P, CARTIER P, FAY WP, GOLDSTEIN MB, JINDAL K, MANDIN H, MCKENZIE JK, MUIRHEAD M, PARFREY PS, POSEN GA, SLAUGHTER D, ULAN RA, WERB R: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214-234, 1992
17. SWEDBERG SH, BROWN BG, SIGLEY R, WIGHT TN, GORDON D, NOCHOLLS SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Circulation 80:1726-1736, 1989
18. SOTTIURAI VS, YAO JST, FLINN WR, BATSON RC: Intimal hyperplasia and neointima: An ultrastructural analysis of thrombosed grafts in humans. Surgery 93:809-817, 1983
19. PAINTER TA: Myointimal hyperplasia: Pathogenesis and implications. Artif Organs 15:42-55 & 103-118, 1991
20. SLACK SM, TURITTO VT: Fluid dynamics and hemorheologic considerations. Cardiovasc Pathol 2:11S-21S, 1993
21. HARKER LS, SLIGHTER SJ: Platelet and fibrinogen consumption in man. N Engl J Med 287:999-1005, 1972
22. DEBRAND-PASSARD A, LAJOUS-PETTER A, SCHMIDT R, HERBST R, VON BAEYER H, KRAUSE AA, SCHIFF H: Characteristics of a new low flux membrane, in Improvements in Dialysis Therapy, edited by BALDAMUS CA, MION C, SHALDON S, Basel, Karger, 1989, p. 2-9
23. CASES A, REVERTER JC, ESCOLAR G, SANZ C, LOPEZ-PEDRET J, REVERT L, ORDINAS A: Platelet activation on hemodialysis: Influence of dialysis membrane. Kidney Int 43:S217-S220, 1993
24. HARKER LA, KADATZ RA: Mechanism of action of dipyridamole. Thromb Res 30 (Suppl IV):39-46, 1983
25. BEST LC, MCGUIRE MB, JONES PBB, HOLLAND TK, MARTIN TJ, PRESTON FE, SEGAL DS, RUSSELL RGG: Mode of action of dipyridamole on human platelets. Thromb Res 16:367-379, 1979
26. MEHTA J, MEHTA P, PEPINE C, CONTI R: Platelet function studies in coronary artery disease. Effects of dipyridamole. Am J Cardiol 47:1111-1114, 1981
27. MASOTTI G, POGESTI L, GALANTI G, NERI-SERNERI CG: Stimulation of prostacyclin by dipyridamole. (abstract) Lancet I:1412, 1979
28. WEBER E, HAAS TA, MULLER TH, EISERT WG, HIRSH J: Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: Influence of salicylate and dipyridamole treatment. Thromb Res 57:383-392, 1990
29. GROVES HM, KINLOUGH-RATHBONE RL, CAZENAVE J-P, DEJANA E, RICHARDSON M, MUSTARD JF: Effect of dipyridamole and prostacyclin on rabbit platelet adherence in vitro and in vivo. J Lab Clin Med 99:548-558, 1982
30. MAMMEN EF: An overview of dipyridamole. Thromb Res 60 (Suppl XII): 1-3, 1990
31. TAKEHARA K, IGARASHI A, ISHIBASHI Y: Dipyridamole specifically decreases platelet derived growth factor release from platelets. Thromb Res 60 (Suppl XII):73-79, 1990
32. SANZ G, PAJARON A, ALEGRIA E, COELLO I, CARDONE M, FOURNIER JA, GOMEZ-RECIO M, RUANO J, HIDALGO R, MEDINA A, OLLER G, COLMAN T, MALPARTIDA F, BOSCH X, GESIC: Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation 82:765-773, 1990
33. ANTIPLATELET TRIALISTS' COLLABORATION: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296:320-331, 1988
34. SCHWAB SJ, QUARLES LD, MIDDLETON JP, COHAN RH, SAEED M, DENNIS VW: Hemodialysis-associated subclavian vein stenosis. Kidney Int 33:1156-1159, 1988
35. SCHWAB SJ, RAYMOND JR, SAEED M, NEWMAN GE, DENNIS PA, BOLLINGER RR: Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int 36:707-711, 1989
36. NEWMAN GE, SAEED M, HIMMELSTEIN S, COHAN RH, SCHWAB SJ: Total central vein obstruction: Resolution with angioplasty and fibrinolysis. Kidney Int 39:761-764, 1991
37. NAKAO J, ITO H, CHANG WC, KOSHIHARA Y, MUROTA S: Aortic smooth muscle cell migration caused by platelet-derived growth factor is mediated by lipoxygenase product(s) of arachidonic acid. Biochem Biophys Res Commun 112:866-871, 1983
38. NAKAO J, KOSHIHARA Y, ITO H, MUROTA S, CHANG WC: Enhancement of endogenous production of 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid in aortic smooth muscle cells by platelet-derived growth factor. Life Sci 37:1435-1442, 1985
39. RINDER CS, STUDENT LA, BONAN JL, RINDER HM, SMITH BR: Aspirin does not inhibit adenosine diphosphate induced platelet alpha-granule release. Blood 82:505-512, 1993
40. WEKSLER BB, PETT SB, ALONSO D, RICHTER RC, STELZER P, SUBRAMANIAN V, TACK-GOLDMAN K, GAY WAJ: Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308:800-805, 1983
41. REMUZZI G, MARCHESI D, SCHIEPPATI A. POLETTI E, MECCA G, ROSSI EC, DONATI MB, GAETANO GD: Aspirin and thrombosis in patients undergoing hemodialysis. (letter) N Engl J Med 302:1420-1421, 1980
42. LIVIO M, BENIGNI A, VIGANO G, MECCA G, REMUZZI G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414-416, 1986
43. REMUZZI G, BENIGNI A, DODESINI P, SCHIEPPATI A, GOTTI E, LIVIO M, MECCA G, DONATI MB, DEUAETANO G: Platelet function in patients on maintenance hemodialysis: Depressed or enhanced? Clin Nephrol 17:60-63, 1982
44. ESQUIVEL CO, BJORCK C, BERGENTZ S, BERGQUIST D, LARSSON R, CARSON SN, DOUGAN P, NILSSON B: Reduced thrombogenic characteristics of expended polytetrafluoroethylene and polyurethane arterial grafts after heparin bonding. Surgery 95:102-107, 1984
45. WILSON NV, SALISBURY JR, KAKKAR VV: Effect of low molecular weight heparin on intimal hyperplasia. Br J Surg 78:1381-1383, 1991
46. NAKAGAWA Y, OTA K, TERAOKA S, AGISHI T: Experimental studies on improved polyester-polyurethane vascular grafts for hemodialysis. ASAIO Trans 37:M273-M274, 1991
47. GRAHAM LM, BROTHERS TE, VINCENT CK, BURKEL WE, STANLEY JC: The role of endothelial cell lining in limiting distal anastomotic intimal hyperplasia of 4-mm-I.D. Dacron grafts in a canine model. J Biomed Mater Res 25:525-533, 1991
48. DISKIN CJ, STOKES JTJ, PENNELL AT: Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 64:1-26, 1993